Ana-Maria Cioca
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ana-Maria Cioca has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
- Ioniță Ducu
Department of Obstetrics and Gynecology, University Emergency Hospital, 169 Splaiul Independentei Bld., Sector 5, 050098 Bucharest, Romania
2 shared publications - Roxana Elena Bohiltea
Department of Obstetrics and Gynecology, Carol Davila University of Medicine and Pharmacy, 020021 Bucharest, Romania
2 shared publications Alex Gabriel Strajean
Department of Obstetrics and Gynecology, Carol Davila University of Medicine and Pharmacy
1 shared publication- Alexandru George Filipescu
Department of Obstetrics and Gynecology, Elias Emergency University Hospital, Carol Davila University of Medicine and Pharmacy, 020021 Bucharest, Romania
1 shared publication Alexandru-George Filipescu
Department of Obstetrics and Gynecology, Elias University Emergency Hospital
1 shared publication- Alexia-Teodora Bohiltea
École Hôtelière de Lausanne, 1000 Lausanne, Switzerland
1 shared publication
Latest Publications
- Open Access
- 21 September 2026
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 16, 1970684
Case Report: Primary malignant melanoma of the uterine cervix with early recurrence following radical surgery and immunotherapy
Background: Primary malignant melanoma of the uterine cervix (PMMC) is an exceptionally rare mucosal malignancy with an aggressive clinical behavior and no established standard of care. Distinguishing a primary cervical melanoma from metastatic disease is particularly challenging and requires integration of pathological findings with comprehensive evaluation for an alternative primary site. Case presentation: We report a 67-year-old postmenopausal woman presenting with vaginal bleeding and an apparently benign endocervical polyp. Histopathological and immunohistochemical examination established the diagnosis of malignant melanoma, with diffuse SOX10, melanoma cocktail, and PRAME positivity and a Ki-67 proliferation index of approximately 40–45%. Molecular testing showed no detectable BRAF mutation. Dermatological assessment and systemic imaging identified no alternative primary melanoma or evidence of distant metastatic disease at initial staging. The patient underwent radical hysterectomy with bilateral pelvic lymphadenectomy and para-aortic lymphadenectomy and omental biopsy. Pelvic lymphadenectomy included bilateral external iliac nodal dissection, with no metastatic involvement identified in the examined lymph nodes. Postoperative pembrolizumab was subsequently initiated. Despite apparently localized disease and multimodal treatment, biopsy-confirmed vaginal recurrence developed approximately two months after surgery. Restaging 18 F-FDG PET/CT demonstrated metabolically active disease involving the vaginal cuff and vagina, together with findings suspicious for external iliac nodal and hepatic involvement. Palliative external-beam radiotherapy was subsequently administered for hemostatic and locoregional control. Conclusion: This case highlights the aggressive and unpredictable course of PMMC, with early histologically confirmed recurrence following radical surgery and postoperative immune checkpoint inhibition. The rapid progression observed in our patient, considered alongside the heterogeneous responses to PD-1 blockade reported in the literature, underscores the therapeutic uncertainty surrounding this rare malignancy and the need for improved predictors of treatment response.
- 21 September 2026
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 16, 1970684
Open AccessCase Report: Primary malignant melanoma of the uterine cervix with early recurrence following radical surgery and immunotherapy
Background: Primary malignant melanoma of the uterine cervix (PMMC) is an exceptionally rare mucosal malignancy with an aggressive clinical behavior and no established standard of care. Distinguishing a primary cervical melanoma from metastatic disease is particularly challenging and requires integration of pathological findings with comprehensive evaluation for an alternative primary site. Case presentation: We report a 67-year-old postmenopausal woman presenting with vaginal bleeding and an apparently benign endocervical polyp. Histopathological and immunohistochemical examination established the diagnosis of malignant melanoma, with diffuse SOX10, melanoma cocktail, and PRAME positivity and a Ki-67 proliferation index of approximately 40–45%. Molecular testing showed no detectable BRAF mutation. Dermatological assessment and systemic imaging identified no alternative primary melanoma or evidence of distant metastatic disease at initial staging. The patient underwent radical hysterectomy with bilateral pelvic lymphadenectomy and para-aortic lymphadenectomy and omental biopsy. Pelvic lymphadenectomy included bilateral external iliac nodal dissection, with no metastatic involvement identified in the examined lymph nodes. Postoperative pembrolizumab was subsequently initiated. Despite apparently localized disease and multimodal treatment, biopsy-confirmed vaginal recurrence developed approximately two months after surgery. Restaging 18 F-FDG PET/CT demonstrated metabolically active disease involving the vaginal cuff and vagina, together with findings suspicious for external iliac nodal and hepatic involvement. Palliative external-beam radiotherapy was subsequently administered for hemostatic and locoregional control. Conclusion: This case highlights the aggressive and unpredictable course of PMMC, with early histologically confirmed recurrence following radical surgery and postoperative immune checkpoint inhibition. The rapid progression observed in our patient, considered alongside the heterogeneous responses to PD-1 blockade reported in the literature, underscores the therapeutic uncertainty surrounding this rare malignancy and the need for improved predictors of treatment response.
- Open Access
- 25 December 2024
- Published by MDPI AG in Current Oncology
- Vol. 32 (1) , 4
Vulvar Metastasis in Renal Cell Carcinoma: A Case Report Highlighting the Aggressive Nature of Clear Cell Renal Cell Carcinoma
Vulvar cancer is one of the rarest gynecological malignancies. The development of this condition can be associated with either dysplasia linked to human papillomavirus (HPV), primarily affecting younger women, or vulvar dermatoses such as lichen sclerosus, which predominantly affect older women. Over the last decade, the incidence of vulvar cancer has risen by 0.6% annually, while the relative survival rate has declined. Although metastasis to the vulva is uncommon, it can occur, particularly from cancers in nearby organs such as the cervix, bladder, rectum, or anus. More rarely, metastases from breast cancer and renal cell carcinoma have been reported in the vulva. Vaginal metastases from clear cell renal carcinoma are especially rare. In this article, we present the case of a 56-year-old patient diagnosed with clear cell renal carcinoma, who came to our clinic with a lesion on the right labia, which was identified as a metastasis originating from the kidney. Given the rarity of genital metastases in renal cancer, such cases should be examined and discussed to encourage further research and studies.
- 25 December 2024
- Published by MDPI AG in Current Oncology
- Vol. 32 (1) , 4
Open AccessVulvar Metastasis in Renal Cell Carcinoma: A Case Report Highlighting the Aggressive Nature of Clear Cell Renal Cell Carcinoma
Vulvar cancer is one of the rarest gynecological malignancies. The development of this condition can be associated with either dysplasia linked to human papillomavirus (HPV), primarily affecting younger women, or vulvar dermatoses such as lichen sclerosus, which predominantly affect older women. Over the last decade, the incidence of vulvar cancer has risen by 0.6% annually, while the relative survival rate has declined. Although metastasis to the vulva is uncommon, it can occur, particularly from cancers in nearby organs such as the cervix, bladder, rectum, or anus. More rarely, metastases from breast cancer and renal cell carcinoma have been reported in the vulva. Vaginal metastases from clear cell renal carcinoma are especially rare. In this article, we present the case of a 56-year-old patient diagnosed with clear cell renal carcinoma, who came to our clinic with a lesion on the right labia, which was identified as a metastasis originating from the kidney. Given the rarity of genital metastases in renal cancer, such cases should be examined and discussed to encourage further research and studies.
- Open Access
- 3 November 2022
- Published by MDPI AG in Diagnostics
- Vol. 12 (11) , 2675
Current Innovative Methods of Fetal pH Monitoring—A Brief Review
In this study, we explore the “why?”, and “how?”, monitoring the pH of the fetal scalp is used, and show its limitations. In addition, we review the development of new devices based on the modern physics and nanomaterials serving this topic. Most of the works we found in our search have focused on improving the prognostic of fetal heart rate monitoring, because it is the “golden standard” in determining fetal distress. Although the best-known screening method, it can only provide limited information about the actual status of the fetus. The best predictive assessment, with the highest reproducibility, states that a normal fetal heart rate is indicative of a healthy baby. However, its excellent sensitivity is much reduced when identifying the actual “distress”. This is when second-line monitoring methods come into play to guide the diagnostics and direct the obstetrician towards an action plan. Although a historic method, fetal scalp pH sampling is still under review as to its efficiency and place in the current obstetrics. Continuous surveillance of the fetal parameters is important, especially for the fetuses undergoing intrauterine growth restricted (IUGR). Since fetal scalp blood sampling is still under research and is a randomized controlled trial, which compares the relevance of pH and lactates to the obstetrical situation, the maternal-fetal medicine could greatly benefit from the introduction of engineered nanomedicines to the field.
- 3 November 2022
- Published by MDPI AG in Diagnostics
- Vol. 12 (11) , 2675
Open AccessCurrent Innovative Methods of Fetal pH Monitoring—A Brief Review
In this study, we explore the “why?”, and “how?”, monitoring the pH of the fetal scalp is used, and show its limitations. In addition, we review the development of new devices based on the modern physics and nanomaterials serving this topic. Most of the works we found in our search have focused on improving the prognostic of fetal heart rate monitoring, because it is the “golden standard” in determining fetal distress. Although the best-known screening method, it can only provide limited information about the actual status of the fetus. The best predictive assessment, with the highest reproducibility, states that a normal fetal heart rate is indicative of a healthy baby. However, its excellent sensitivity is much reduced when identifying the actual “distress”. This is when second-line monitoring methods come into play to guide the diagnostics and direct the obstetrician towards an action plan. Although a historic method, fetal scalp pH sampling is still under review as to its efficiency and place in the current obstetrics. Continuous surveillance of the fetal parameters is important, especially for the fetuses undergoing intrauterine growth restricted (IUGR). Since fetal scalp blood sampling is still under research and is a randomized controlled trial, which compares the relevance of pH and lactates to the obstetrical situation, the maternal-fetal medicine could greatly benefit from the introduction of engineered nanomedicines to the field.
- Open Access
- 31 December 2021
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 11 (1) , 214
Expectant Management of PPROM Improves Neonatal Outcome—A Retrospective Study of 562 Patients
Prelabor preterm rupture of the membranes (PPROM) refers to the rupture of the membranes before 37 weeks, but also before the onset of labor. Approximately 3% of pregnancies are complicated by PPROM, which is an important cause of neonatal morbidity and mortality. The aim of the study is to demonstrate the benefit of expectant management in PPROM, compared to immediate birth, defined in our study as birth in the first 48 h. We analyzed 562 pregnancies with PPROM by gestational age groups and short-term morbidities. Material and methods: We conducted a retrospective observational analytical study, which included women with PPROM between 24 + 0 and 36 + 6 weeks. We divided the cohort into gestational age groups: group 1 gestational age (GA) between 24 and 27, group 2 GA between 28 and 31, group 3 GA between 32 and 34, group 4 GA > 35 weeks. In each group, we analyzed the benefit of the latency period (established in our study as delivery after 48 h of hospitalization) in terms of short-term neonatal complications. Result: The latency period brought a significant benefit starting with GA greater than 28 weeks; therefore, in the group with GA between 28–31, the complications were significantly statistically lower, mentioning respiratory distress syndrome (no latency 100% vs. latency 85.1%) and admission to the neonatal intensive care unit (no latency 89.7% vs. latency 70.2%). In group 3, with GA between 32–34, we reached statistical significance in terms of respiratory distress syndrome (no latency 61.8% vs. latency 39%), hypoxia (no latency 50% vs. latency 31.7%) and admission to the neonatal intensive care unit (no latency 70.2% vs. latency 47.4%). Conclusion: Expectant management of pregnancies with PPROM can bring a real benefit in terms of the incidence of complications in premature infants, but this benefit depends most on the gestational age at which the membranes ruptured and the medical conduct put into practice during the latency period.
- 31 December 2021
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 11 (1) , 214
Open AccessExpectant Management of PPROM Improves Neonatal Outcome—A Retrospective Study of 562 Patients
Prelabor preterm rupture of the membranes (PPROM) refers to the rupture of the membranes before 37 weeks, but also before the onset of labor. Approximately 3% of pregnancies are complicated by PPROM, which is an important cause of neonatal morbidity and mortality. The aim of the study is to demonstrate the benefit of expectant management in PPROM, compared to immediate birth, defined in our study as birth in the first 48 h. We analyzed 562 pregnancies with PPROM by gestational age groups and short-term morbidities. Material and methods: We conducted a retrospective observational analytical study, which included women with PPROM between 24 + 0 and 36 + 6 weeks. We divided the cohort into gestational age groups: group 1 gestational age (GA) between 24 and 27, group 2 GA between 28 and 31, group 3 GA between 32 and 34, group 4 GA > 35 weeks. In each group, we analyzed the benefit of the latency period (established in our study as delivery after 48 h of hospitalization) in terms of short-term neonatal complications. Result: The latency period brought a significant benefit starting with GA greater than 28 weeks; therefore, in the group with GA between 28–31, the complications were significantly statistically lower, mentioning respiratory distress syndrome (no latency 100% vs. latency 85.1%) and admission to the neonatal intensive care unit (no latency 89.7% vs. latency 70.2%). In group 3, with GA between 32–34, we reached statistical significance in terms of respiratory distress syndrome (no latency 61.8% vs. latency 39%), hypoxia (no latency 50% vs. latency 31.7%) and admission to the neonatal intensive care unit (no latency 70.2% vs. latency 47.4%). Conclusion: Expectant management of pregnancies with PPROM can bring a real benefit in terms of the incidence of complications in premature infants, but this benefit depends most on the gestational age at which the membranes ruptured and the medical conduct put into practice during the latency period.